In pancreatic cancer, SOX2 makes pancreatic cancer cells resistant to gemcitabine through the GLI-SOX2 axis 8, and it controls the stemness of pancreatic cancer cells through FGFR/AKT/SOX2, which is a potential therapeutic target 9. Here, AKT1 is linked to pancreatic neoplasm.